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We originally reported that members of the family of
transcription factors NF-kB/Rel can specifically recog-
nize two identical sequences, referred to as APPkB sites,
which are present in the 5*-regulatory region of the APP
gene. Here we show that the APPkB sites interact spe-
cifically with a complex which contains one of the sub-
units of the family, defined as p50 protein, and that they
act as positive modulators of gene transcription in cells
of neural origin. Additionally, the nuclear complex spe-
cifically binding to the APPkB sites is constitutively
expressed in primary neurons from rat cerebellum and
it is up-regulated in response to both the inflammatory
cytokine interleukin-1b (IL-1b) and the excitatory
amino acid glutamate. Since IL-1, whose levels are
known to be induced in brain of individuals affected by
Alzheimer’s disease, and glutamate, are stimuli which
have been regarded as major actors on the stage of neu-
rodegenerative processes, we believe our evidence as
potentially relevant for understanding the neuropathol-
ogy associated with Alzheimer’s disease.
Alzheimer’s disease (AD)1 is a neurodegenerative disorder
characterized by abnormal deposition of extracellular congo-
philic plaques in the brain. The main constituent of plaques is
a 39- to 43-amino acid peptide, named b-amyloid, which is a
proteolytic fragment of the amyloid precursor protein (APP) (1).
In recent years, most experimental studies have been aimed at
understanding the mechanisms of b-amyloid formation and
deposition and at identifying potential risk factors which may
favor these processes. In particular, APP gene mutations oc-
curring in families with Familial AD have been correlated with
disturbance in protein processing, which in turn, may predis-
pose to b amyloid formation (2, 3). However, since APP gene
mutations represent a minor percentage of AD cases, it is
evident that other mechanisms may exist to account for b-amy-
loid deposition. In this regard, it should not be underestimated
that overexpression of the APP gene may be involved in the
pathogenetic mechanisms of amyloid formation, at least in
some clinical forms of the disease. Several observations under-
score the potential contribution of the APP gene overexpression
to favoring AD neuropathology: (i) the marked accumulation of
b-amyloid which correlates with increased levels of APP mRNA
in trisomy 21 (Down’s syndrome) (4); (ii) the increased levels of
APP gene transcripts in specific areas of the AD brains (5–7);
(iii) the increased APP mRNA transcription in cultured fibro-
blasts from the Familial Alzheimer’s disease-1 family (8). In
addition, post-mitotic neurons which overexpress full-length
APP were shown to degenerate and accumulate large amounts
of amyloidogenic C-terminal fragments (9). The promoter re-
gion of the APP gene (10) has been shown to contain binding
sequences for several known transcription factors (11–19). We
reported recently (20) that a novel regulatory pathway for APP
gene control at the transcriptional level may involve members
of the NF-kB/Rel family. This family of transcription factors is
composed of several members (including p50, p52, p65 or RelA,
c-Rel, and RelB) that form hetero- and homodimers which are
able to trigger signaling from cell membrane to nucleus. In
most cell types, these regulators mediate an early pathogen
response by coordinately initiating transcription of genes in-
volved in inflammatory, immune, and acute phase responses
(21, 22). In particular, we demonstrated that two identical
decameric sequences corresponding to 59-GGGGTTTCAC-39,
located in the 59-regulatory region of the APP gene, are able to
specifically bind NF-kB/Rel proteins (20). The sites, which we
referred to as APPkB sites, interact with a kB complex which is
constitutively expressed in different rat brain areas and in
several cell lines, where levels of this DNA binding activity
correlates with APP mRNA content. Furthermore, these sites
behave as positive modulators of gene transcription when in-
teracting with members of the family of transcription factors
containing the p50 subunit. We now report that an APPkB
binding activity, with the same electrophoretic migration prop-
erties, affinity, and immunogenicity as the one previously iden-
tified from rat brain areas and cell lines of various origin, is
present in primary neurons and in neuroblastoma cells. In the
attempt to identify the extracellular signals that may contrib-
ute to regulate APP gene expression through APPkB sites, we
selected IL-1 and glutamate as good candidates for such a
modulatory role. In fact IL-1 is induced in the central nervous
system following a variety of insults (23). Moreover, the cyto-
kine is dramatically overexpressed in brains of individuals
with AD and Down’s syndrome (24) and it induces an increase
in APP transcript levels in endothelial (11) and neuronal cells
(25). On the other hand, the role of glutamate as a mediator of
acute neurodegenerative events is well recognized (26). Here
we report that both IL-1 and glutamate can indeed up-regulate
the specific APPkB binding activity in primary neuronal cul-
tures. In transfection experiments the APPkB site proves to be
sufficient to mediate IL-1-induced transcription of a reporter
gene.
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The contribution of these findings to a better understanding
of the pathogenetic mechanisms underlying AD could be rele-
vant. Our working hypothesis is that NF-kB/Rel proteins can
mediate gene expression in response to pathogenic events not
only in “periphery,” but also in brain. We suggest that the APP
gene is one of the kB-controlled genes in the central nervous
system and that this genetic response may potentially contrib-
ute to the pathogenesis of AD.
EXPERIMENTAL PROCEDURES
Cell Culture—Primary cultures of cerebellar granule cells were pre-
pared from cerebella of 8-day-old rat pups (Sprague-Dawley), as de-
scribed previously (27). 12 3 106 cells were plated onto 100-mm Petri
dishes coated with 100 mg/ml L-polylysine and grown in basal medium
Eagle’s containing 10% fetal calf serum, 2 mM glutamine, 25 mM KCl,
and gentamycin (50 mg/ml). Cells were utilized after 12 days of cultur-
ing. The human neuroblastoma SH-SY5Y cell line was grown in mini-
mum essential medium with 10% fetal calf serum, 2 mM glutamine,
penicillin (100 units/ml), and streptomycin (100 mg/ml).
Nuclear Extracts and Electrophoretic Mobility Shift Assay—Nuclear
extracts from cell lines and from primary cultures were prepared ac-
cording to a small scale protocol as in Ref. 28. Protein concentration was
assessed by the Bio-Rad Bradford assay according to the manufactur-
er’s instructions. DNA binding reactions were initiated by combining
2–4 mg of nuclear extracts with 20,000 cpm (0.1 ng) of g-32P-labeled
oligonucleotides in 1 3 lipage buffer (10 mM Tris-Cl, pH 7.5, 50 mM
NaCl, 1 mM dithiothreitol, 1 mM EDTA, 10% glycerol) containing 0.5 mg
of poly(dI-dC) in a total volume of 10 ml. In competition experiments, 2
ng (20-fold molar excess) of unlabeled competitor oligonucleotides were
added together with 32P-labeled probes. Reactions were carried out for
20 min at room temperature, and protein-DNA complexes were resolved
on nondenaturing 4% polyacrylamide gels in 1 3 Tris glycine-EDTA
buffer. Gels were then dried and subjected to autoradiography at room
temperature. In supershift experiments, 1 ml of preimmune or immune
serum was incubated with nuclear extracts for 1 h at 4 °C, before
addition of the other components of the reaction mixture and incubation
for an additional 20 min at room temperature. Polyclonal rabbit anti-
p50 antibodies were prepared against bacterially produced and affinity
purified recombinant mouse p50 as described in Ref. 29, anti-p65 and
anti-c-Rel antibodies were from Santa Cruz Biotechnologies.
Synthetic DNA Oligonucleotides—Oligonucleotides were synthe-
sized, together with their complementary strands, using a DNA syn-
thesizer (Applied Biosystem), and purified by denaturing gel electro-
phoresis. For gel shift analysis double-stranded oligonucleotides were
end-labeled with [g-32P]ATP (ICN, specific activity .7,000 Ci/mmol)
and T4 polynucleotide kinase (Boehringer Mannheim) to obtain a spe-
cific activity of more than 108 cpm/mg. Sequences were as follows: APP1
(22257 to 22234 of the APP 59-regulatory region) 59-TA-
GAGACGGGGTTTCACCGTGTTA-39; APP2 (21894 to 21871 of the
APP 59-regulatory region), 59-AGAGATGGGGGTTTCACCATGTTG-39;
mutAPP1, 59-TAGAGACGctcTTTCACCGTGTTA-39; oligonucleotide
containing the octamer protein binding site from the interleukin-2 gene
enhancer region, 59-TATGTGTAATATGTAAAACATTTTGACACC-39;
IL-2kB (2212 to 2195 of the interleukin-2 gene enhancer region),
59-CCAAGAGGGATTTCACCTAAATCC-39. Both strands of the APP
oligonucleotide probes have a 59-TCGA-39 overhang at their 59 end to
facilitate cloning.
Plasmid Constructs—Oligonucleotides representing the two putative
kB sites from the APP gene regulatory region, APP1 and APP2, were
subcloned into the SalI restriction site of PBLCAT2 (30) to generate
APP1kBCAT and APP2kBCAT constructs, as described in Ref. 20.
Transfection of Cell Lines—SH-SY5Y cells (5 3 105 cells/60-mm
dishes) were transiently transfected with 10 mg of APP1kBCAT,
APP2kBCAT, or PBLCAT2 using the calcium phosphate technique.
Four hours after calcium phosphate-DNA addition to cell medium, cells
were washed twice with serum-free medium followed by culturing in
complete medium. 24 h later, either human recombinant IL-1b (Boeh-
ringer Mannheim), 250 units/ml, or phosphate-buffered saline was
added to culture medium. After 16–18 h, cells were collected, washed in
phosphate-buffered saline, and lysed by three cycles of freezing and
thawing in 250 mM Tris-Cl, pH 7.5. Supernatants obtained by centrif-
ugation for 5 min at 12,000 rpm were sampled to determine protein
content and assayed for chloramphenicol acetyltransferase (CAT) ac-
tivity according to Ref. 31. Transfection efficiency throughout the ex-
periments was monitored by cotransfection with pSVbgal plasmid.
Transfection experiments were repeated three times in duplicate with
at least two independent plasmid preparations.
Northern Blot Analysis—Total RNA was extracted with RNAzol from
10 3 106 cerebellar granule cells maintained in culture for 12 days and
treated as described, according to the manufacturer’s instructions. Ali-
quots (20 mg) of RNA were separated on 1.2% agarose-formaldehyde
gels and transferred to nylon filters (Hybond N-plus, Amersham). A
1.0-kilobase EcoRI fragment of a mouse cDNA clone representing the
b-amyloid and the proximal 39-untranslated region of APP (a kind gift
of Dr. G. Forloni), was used to measure b-APP mRNA transcripts. The
cDNA probe was labeled using a randomly primed DNA labeling kit
from Amersham, according to the manufacturer’s instructions. Hybrid-
ization conditions were the same as described previously (25). Blots
were exposed to x-ray films at 280 °C with intensifying screens for the
time necessary for the signal to be in the linear range for quantification.
GAPDH mRNA was measured in each sample and used as an internal
control to normalize for total RNA. Hybridization was quantified by
densitometry and expressed as APP/GAPDH ratio.
RESULTS
The DNA Binding Activity Interacting with the APPkB Site Is
Constitutively Present in Primary Neurons—Nuclear extracts
were prepared from primary cultures of rat cerebellar granule
cells. These cultures consist of a highly homogenous population
of neurons. In fact, over 95% of these cells are glutamatergic
granule cells, with minimal contamination (less than 3%) by
glial and endothelial elements. The experiments were per-
formed on the 12th day of culturing. Extracts were then tested
in electrophoretic mobility shift assay (EMSA) for the presence
of specific activities able to interact with the APPkB site. Dou-
ble-stranded oligonucleotides comprising the APPkB sites from
the 59-regulatory region of the APP gene and designated as
APP1 (22257 to 22234) and APP2 (21894 to 21871) were
utilized. The results from representative experiments using
g32P-labeled APP1 probe are shown in Fig. 1; comparable re-
sults were obtained with the APP2 oligonucleotide (data not
shown). The APP1 probe detected a single complex (Fig. 1, lane
1) which proved to be a specific DNA binding activity, since it
could be displaced by a 20-fold molar excess of the unlabeled
APP1 oligonucleotide (lane 2), and not by an unrelated oligo-
nucleotide probe (containing an octamer binding site) (lane 4)
or by a mutated version of the APP1 oligonucleotide with three
base changes in the kB-like core sequence (lane 5). Further-
more, to confirm that the nuclear complex was a NF-kB/Rel-
related complex, a competition experiment was performed also
with an oligonucleotide containing a well characterized kB site
from the IL-2 gene enhancer region (29). As shown in Fig. 1,
lane 3, the IL-2kB oligonucleotide competed with the APP1
sequence for binding to the nuclear complex.
The APPkB Binding Complex from Cerebellar Granule Cells
Is Immunologically Related to the p50 Subunit of the NFkB/Rel
Family—In order to obtain further information on the subunit
composition of the APPkB complex identified in primary neu-
rons, antibodies specific for several members of the NF-kB/Rel
family were tested for their ability either to interfere with DNA
binding or to supershift DNA bound activity. Nuclear extracts
were incubated with the g-32P-labeled APP1 probe in the pres-
ence of polyclonal antibodies raised against p50, p65, and c-Rel
subunit. As shown in Fig. 1, lane 6, the p50 antiserum inter-
acted with the APPkB binding complex causing a supershift of
bound probe. No interaction was observed by incubating the
extracts with the anti-p65 (lane 7) and anti-c-Rel antisera (lane
8). Specificity of results was confirmed with preimmune serum
or by incubating the antisera with the peptides against which
they were raised (not shown). In conclusion, an APPkB binding
activity, with the same affinity properties and immunogenicity
as the one previously identified from rat brain areas and cell
lines of various origin (20), is also present in primary neurons.
The Neuronal APPkB Binding Activity Can Be Up-regulated
by Interleukin 1b—Wewere interested in verifying whether the
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neuronal APPkB binding activity could be activated by those
extracellular signals that have been proposed to be involved in
the chain of events leading to increased APP transcription.
Primary cultures of rat cerebellar granule cells were either
untreated or treated with increasing concentrations (25, 250,
500 units/ml) of recombinant human IL-1b for 1 h. Nuclear
extracts were prepared and analyzed by EMSA. As shown in
Fig. 2, IL-1b was able to significantly augment APPkB binding
activity compared to untreated cells. The induction was dose-
dependent, with maximal activity at a concentration of 250
units/ml. Time dependence of this effect was evaluated as well.
Cells were exposed to a dose of 250 units/ml recombinant hu-
man IL-1b for different times (30 min, 1 h, 3 h). Nuclear
extracts were prepared and analyzed by gel shift assay with
APP1 and APP2 oligonucleotide probes. As shown in Fig. 3A,
IL-1b up-regulation of APPkB binding activity was already
detectable after 15 min, with maximal increase within 1 h.
After 3 h of stimulation, APPkB binding activity was still above
controls. In each experiment, quality and quantity of nuclear
extract samples were evaluated using, as internal control, an
unrelated oligonucleotide probe containing a consensus se-
quence for octamer-binding proteins, which are unaffected by
the cytokine (not shown). Additionally, under the same exper-
imental conditions, exposure of cerebellar granule cells in cul-
ture to 250 units/ml IL-1b resulted in a significant increase in
APP transcripts. The increase became detectable as early as
6 h (not shown), but only after 12 h of stimulation APP mRNA
content was about 2–3-fold higher than that of untreated cells,
as depicted in Fig. 3B.
Transcriptional Activation of the APPkB Site by IL-1b in the
Human Neuroblastoma Cell Line SH-SY5Y—To directly deter-
mine if the APPkB site is sufficient to confer transcriptional
response in cells of neural origin, we transiently transfected
human neuroblastoma cell line SH-SY5Y, which is known to
express the APP gene, with 10 mg of the reporter construct
APP1kBCAT, obtained by cloning the APP1 oligonucleotide
fused to a heterologous promoter in the expression vector
PBLCAT2 (30). As depicted in Fig. 4A, no difference in reporter
gene activity was observed between cells transfected with
PBLCAT2 or APP1kBCAT vectors. On the contrary, in cells
transfected with APP1kBCAT, 250 units/ml IL-1b stimulated a
4-fold increase in promoter activity compared to cells trans-
fected with the control plasmid. Analogous results were ob-
tained with the APP2kBCAT reporter vector (obtained by clon-
ing the APP2 oligonucleotide in PBLCAT2, not shown) and in
another human neuroblastoma cell line, SK-N-SH (not shown).
The APPkB-mediated Transcriptional Activity Correlates
with Levels of APPkB Binding Activity—To determine whether
IL-1b induces APPkB binding activity in SH-SY5Y cells, we
performed a gel shift experiment. Nuclear extracts were pre-
pared from neuroblastoma cells which were unstimulated (con-
trol) or stimulated with 250 units/ml of IL-1b for 1, 3, and 6 h.
As shown in Fig. 4B, in untreated cells we detected a very low
amount of constitutive protein activity binding the APP1 site. A
time dependent increase in DNA binding activity was observed
in IL-1b-stimulated cells, with a maximal increase after 3 h of
stimulation. Specificity of DNA-protein interaction was con-
firmed by competition experiments with the unlabeled oligonu-
FIG. 1. Characterization of the APPkB binding activity in nu-
clear extracts of cerebellar granule cells. EMSA was performed
using g-32P-labeled APP1 oligonucleotide as a probe. Specificity of DNA-
protein interaction was demonstrated by incubating nuclear extracts in
absence (lane 1) or in presence of unlabeled APP1 (lane 2), IL-2kB (lane
3), an unrelated oligonucleotide containing the binding site for octamer
proteins (lane 4), and a mutated version of APP1 (lane 5), as competi-
tors. Molecular composition of the complex was investigated by incu-
bating nuclear extracts in the presence of antibodies raised against p50
(lane 6), p65 (lane 7), and c-Rel (lane 8) subunits.
FIG. 2. Up-regulation of APPkB binding activity by IL-1b.
EMSA obtained by incubating 4 mg of nuclear extracts from rat cere-
bellar granule cells with g-32P-end labeled APP1 oligonucleotide probe.
Cells were untreated (lane 1) or treated with different concentrations of
IL-1b, as indicated in the upper part of the figure (lanes 2–4).
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cleotide probe (not shown).
The APPkB Binding Activity Is Modulated by the Excitatory
Amino Acid Glutamate—The primary cultures of cerebellar
granule cells are a widely recognized model for studying mech-
anisms of toxicity generated by excitatory amino acids through
the activation of the N-methyl-D-aspartic acid-type of gluta-
mate receptor (27). Activation of this receptor in the absence of
extracellular magnesium permits calcium influx when cells are
stimulated at normal resting membrane potential. In this sys-
tem, glutamate administered under appropriate experimental
conditions (50–200 mM, 15-min pulse, in absence of magne-
sium) which are well documented to induce N-methyl-D-aspar-
tic acid-receptor activation, results in a significant up-regula-
tion of the APPkB binding activity (Fig. 5). Glutamate-
mediated APPkB induction became detectable within 30 min
and was maximal after 15 min (not shown) when 100 mM
glutamate was utilized as a stimulus.
DISCUSSION
Several clinical and experimental observations underscore
the potential contribution of APP gene overexpression to pro-
duction of the b-amyloid peptide and possibly to the neuropa-
thology associated with AD (4–9). In this regard, it appears
important to elucidate the molecular mechanisms of APP gene
regulation and identify in the 59-regulatory region of this gene,
cis-acting regulatory elements and transcription factors poten-
tially relevant for the control of gene expression. APP overex-
pression may indeed result from imbalance among regulatory
pathways for APP expression (i.e. alterations in transcription
factors expression or activation) and/or from mutations in the
APP gene regulatory region.
We have recently reported the identification of two identical
sequences located in the 59-regulatory region of the APP gene
which are specific binding sites for regulatory members of the
NF-kB/Rel family of transcription factors (20). The NF-kB fam-
ily is composed of several distinct DNA binding subunits (in-
cluding p50, p52, or p50B, p65 or RelA, c-Rel, RelB) which can
hetero- and homodimerize, thereby forming complexes with
distinct cell type distribution, DNA sequence specificity, and
transcriptional activity. Properties of these proteins have been
most extensively exploited in cells of the immune system or,
more in general in periphery, where these regulators mediate
an immediate-early pathogen response by coordinately initiat-
ing transcription of genes involved in inflammatory, immune,
and acute-phase responses (21, 22). On the contrary, until
recently the presence and function of NF-kB/Rel proteins in
cells from the nervous system were poorly documented. Some
recent elegant reports have suggested that NF-kB/Rel proteins
are likely to participate in normal and pathological brain func-
tion (32–35). We now show that an APPkB binding activity is
constitutively present in neuronal primary cultures from rat
cerebellum. As far as specificity, affinity, and immunogenicity,
FIG. 3. Effect of IL-1b on APPkB
binding activity and APP mRNA lev-
els in primary neuronal cultures of
cerebellar granule cells. A, gel shift
analysis of nuclear extracts incubated
with 32P-labeled APP1 and APP2 oligonu-
cleotides. Cells were either untreated (2)
or treated (1) with 250 units/ml recombi-
nant IL-1b for 15 min, 1 h, 3 h. B, APP
mRNA levels in untreated (open bar) or
IL-1b-treated (filled bar) cerebellar gran-
ule cells. Quantification of total RNA ex-
tracted from neuronal cells after 12 h ex-
posure to IL-1b (250 units/ml) and
hybridized with cDNA probes recognizing
total APP and GAPDH mRNA. GAPDH
was used as an internal control. Hybrid-
ization was quantified by densitometry
and expressed as APP/GAPDH ratio. The
data are the means 1 S.E. of five deter-
minations. *, p , 0.01 versus control.
FIG. 4. IL-1b induced transcriptional activation of an APPkB
driven reporter plasmid and APPkB binding activity in the
neuroblastoma cell line SH-SY5Y. A, CAT assay performed on 15 mg
of cytosolic extracts from undifferentiated SH-SY5Y cells transfected
with 10 mg of the reporter plasmid APP1kBCAT (obtained by cloning
the APP1 oligonucleotide sequence at the SalI site of PBLCAT2) or of
the parental plasmid PBLCAT2, either in the absence (control) or
presence of 250 units/ml human recombinant IL-1b (1IL-1b). CAT
activities are expressed as fold induction relative to activity obtained
with PBLCAT2. Transfection experiments were repeated three times in
duplicate with at least two independent plasmid preparations. B,
EMSA of nuclear extracts from undifferentiated SH-SY5Y cells un-
treated (2) or treated (1) with 250 units/ml IL-1b for different periods
of time as indicated in the upper part of the figure. g-32P-Labeled APP1
oligonucleotide was used as probe.
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the nuclear complex is identical to the one previously identified
in rat brain, in T lymphocytes and cell lines of various origin
(20). As postulated previously, also in neuronal cultures the
APPkB binding complex appears likely to correspond to a p50
homodimer. More important, the nuclear complex, can be mod-
ulated in a dose- and temporal-specific manner by IL-1b and
glutamate. When the stimulus is IL-1b, induction of DNA
binding activity at the APPkB site can be correlated with a
parallel increase in transcriptional activity of an APPkB-driven
reporter gene and with increase in APP mRNA levels. Addi-
tionally, glutamate can also potently induce the APPkB bind-
ing activity, even at concentrations that are not fully neuro-
toxic. For glutamate, an analogous correlation between APPkB
binding activity and APP mRNA levels was not performed,
since the active concentrations cause neuronal death within
the same time frame. Nevertheless, we have indirect evidence
that glutamate can result in APP gene expression, since under
the same experimental conditions, stimulation of the N-meth-
yl-D-aspartic acid receptor causes a significant increase in APP
immunoreactivity (36).
These data allow us to hypothesize that two major pathoge-
netic pathways which are likely to contribute to the neuropa-
thology associated with Alzheimer’s disease (inflammatory cy-
tokines and excitatory amino acids), although distinct, share a
common step represented by activation of a NF-kB/Rel activity.
This event may ultimately result in APP gene overexpression.
In this respect it should be further extended by the recent
observation, made by Yan and colleagues (37), that NF-kB
activity is significantly augmented in AD brain compared to
controls. Transfer of this knowledge to the understanding of
the neuropathology of AD, although reductive, could contribute
to open novel perspectives in the way we think about the
disease. Our data may indeed support the hypothesis that in
AD both the inflammatory cytokine IL-1b and excitatory amino
acid glutamate can contribute to NF-kB induction and that, in
turn, augmented NF-kB activity can participate in dysregu-
lated expression of the APP gene.
We propose that NF-kB/Rel proteins may represent the point
of convergence of several signaling pathways relevant for ini-
tiating or accelerating those events, like inflammatory media-
tors, excitatory amino acids, and glycated t formation (37), that
ultimately contribute to the process of neuronal dysfunction
and degeneration in AD. To this regard, the APP itself, whose
gene expression is up-regulated in response to several stressing
circumstances including head injury, neurotoxicity, and focal
ischemia (38–43) could be viewed as acute-phase protein. We
speculate that the APP gene may be one of a set of kB-site
containing genes, coordinately modulated in brain in response
to situations that require a defensive reaction. In fact, many of
the genes which are induced in periphery during stress condi-
tions are under control of NF-kB/Rel proteins. Among them it is
the serum amyloid A gene, which encodes for another amyloi-
dogeneic protein (44).
If APP has to be regarded as a reactive protein, somehow
crucial for cellular response to various threatening conditions,
how will this response turn out to be deleterious in AD? We
have a pragmatic working hypothesis. If induction of APP
transcripts, whose original significance is defensive, was inap-
propriate as far as time (prolonged persistence of the noxa,
and/or defect in mechanisms that may restrict/terminate the
response), site (different rates of APP expression may occur in
various brain areas), or intensity, it could result in augmented
production of the b-amyloid. Therefore overexpression of the
APP gene should be regarded as a potential risk factor for
neuritic plaque formation.
If NF-kB/Rel proteins represented an integrating point
which conveys several pathways potentially contributing to the
pathogenesis of AD, molecules that finely modulate their ac-
tivity could also prevent and/or retard the progression of the
disease. More in general, it is a reasonable prospect that this
and other studies on the transcriptional control of the APP
gene may help to develop novel therapeutical strategies to be
applied in AD cases where APP overexpression is highly con-
tributory to occurrence of the disease.
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